Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.
Rezvoglar™(insulin glargine-aglr) – New biosimilar approval
On December 20, 2021, the FDA announced the approval of Eli Lilly’s Rezvoglar (insulin glargineaglr), a biosimilar to Sanofi’s Lantus® (insulin glargine).
